Nanexa AB (NANEXA)
XSTO XSTO Primary Summary
Nanexa AB (NANEXA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Nanexa AB ever had a stock split?
Nanexa AB Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. David Westberg CEO | XSTO Exchange | SE0007074166 ISIN |
| SE Country | 16 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Nanexa AB (publ) is a pioneering pharmaceutical company that specializes in nanotechnology for drug delivery. Founded in 2007, the company has established itself in the pharmaceutical industry through its innovative PharmaShell delivery platform, which uses atomic layer deposition technology to enhance the delivery of drugs. Based in Uppsala, Sweden, Nanexa AB is dedicated to improving treatment outcomes for patients with various diseases by developing advanced drug delivery solutions. The company's focus on leveraging nanotechnology places it at the forefront of the pharmaceutical industry, providing cutting-edge solutions for drug administration.
Products and Services
Nanexa AB's portfolio includes a range of products designed to revolutionize drug delivery through its proprietary PharmaShell technology. Below is an overview of their key developments:
- PharmaShell: A nanobased drug delivery platform that utilizes atomic layer deposition technology. This innovative approach allows for precise control over the drug release profiles, enhancing the efficacy and safety of pharmaceutical compounds.
- NEX-18: A developmental product targeting myelodysplastic syndrome (MDS) and Acute Myeloid Leukemia (AML). NEX-18 aims to improve the treatment of these hematological diseases by utilizing the PharmaShell technology to achieve targeted drug delivery and reduce side effects.
- NEX-20: Focused on the treatment of multiple myeloma, NEX-20 leverages the PharmaShell platform to provide a novel approach to therapy. By optimizing drug release profiles, NEX-20 seeks to offer an effective and safer alternative for patients suffering from this type of cancer.
- NEX-22: Aimed at addressing type 2 diabetes, NEX-22 stands out as a promising solution for improving diabetes management. Through the application of PharmaShell technology, NEX-22 is designed to enhance the delivery and effectiveness of diabetes medications, potentially improving patient outcomes and quality of life.
